

TABLE E-1 Characteristics of Included Randomized Controlled Trials

| Study Author | Year | Number of Patients | | | Mean Age (yr) | Female (%) | Fracture Type | Displacement |
|-------------------------|------|--------------------|-----------|--------------|---------------|------------|------------------------|------------------------|
| | | Total | Operative | Conservative | | | | |
| Adolfsson ³⁰ | 2001 | 53 | 25 | 28 | 31 | 26 | Herbert B1, B2 | None |
| Arora ³¹ | 2007 | 47 | 23 | 24 | 33 | 27 | Herbert B2 | None |
| Bond ¹⁴ | 2001 | 25 | 11 | 14 | 24 | 12 | Herbert A2, B2 | None |
| Dias ³² | 2005 | 88 | 44 | 44 | 30 | 10 | Herbert A2, B2, B5 | 11 minimally displaced |
| McQueen ¹³ | 2008 | 60 | 30 | 30 | 29 | 17 | Herbert B1, B2 | 7 minimally displaced |
| Saedén ³³ | 2001 | 61 | 31 | 30 | 33 | 21 | AO C2, C3 | Not available |
| Vinnars ³⁴ | 2007 | 52 | 26 | 26 | Not available | 31 | Herbert A2, B1, B2, B3 | None |
| Vinnars ¹⁸ | 2008 | 85 | 43 | 42 | 32 | 22 | Herbert A2, B1, B2, B3 | None |

TABLE E-2 Reported Outcomes in Selected Studies

| Outcomes Reported | Adolfsson ³⁰ | Arora ³¹ | Bond ¹⁴ | Dias ³² | McQueen ¹³ | Saedén ³³ | Vinnars ³⁴ (2007) | Vinnars ¹⁸ (2008) |
|-----------------------------|-------------------------|---------------------|--------------------|--------------------|-----------------------|----------------------|------------------------------|------------------------------|
| Functional outcome | | x | | x | x | | | x |
| Patient satisfaction | | | x | | | | | |
| Pain | | x | | x | | | | |
| Range of motion | x | x | x | x | x | x | | x |
| Grip strength | x | x | x | x | x | x | | x |
| Time to union | | x | x | | x | | | |
| Infection | x | x | x | x | x | x | | x |
| Nonunion | x | x | x | x | | x | | x |
| Malunion | x | x | x | x | x | x | | x |
| Return to work | | x | x | x | x | x | x | |
| Return to previous activity | x | | | | x | | | x |
| Costs | | x | | | | | x | |

TABLE E-3 Methodological Quality of Eligible Randomized Controlled Trials

| Characteristics | Adolfsson ³⁰ | Arora ³¹ | Bond ¹⁴ | Dias ³² | McQueen ¹³ | Saedén ³³ | Vinnars ³⁴ (2007) | Vinnars ¹⁸ (2008) |
|-------------------------------------|-------------------------|---------------------|--------------------|--------------------|-----------------------|----------------------|------------------------------|------------------------------|
| Concealment of treatment allocation | Unknown | Unknown | + | + | + | Unknown | + | + |
| Patients blinded | - | - | - | - | - | - | - | - |
| Caregivers blinded | - | - | - | - | - | - | - | - |
| Outcome assessors blinded | - | - | - | - | + | - | - | - |
| Loss to follow-up | 26% | 6% | 0% | 8% | 8% | 18% | 0% | 11% |